Skip to main content
Top
Published in: Virchows Archiv 5/2013

01-05-2013 | Original Article

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus

Authors: Johannes L. Blaauwgeers, Ingrid Kappers, Houke M. Klomp, José S. Belderbos, Lea M. Dijksman, Egbert F. Smit, Pieter E. Postmus, Marinus A. Paul, Jan W. Oosterhuis, Koen J. Hartemink, Cornelis G. Vos, Jacobus A. Burgers, Max Dahele, Erik C. Phernambucq, Birgit I. Witte, Erik Thunnissen

Published in: Virchows Archiv | Issue 5/2013

Login to get access

Abstract

The objective was to define the relationship between histopathological changes after pre-operative chemo-radiotherapy (CRT) and clinical outcome following tri-modality therapy in patients with superior sulcus tumours. A retrospective analysis of tumour material was performed in a series of 46 patients who received tri-modality therapy between 1997 and 2007. Median follow-up was 34 months (5–154). Pathological complete response (pCR) was present in 20/46 tumours (43 %). The most common RECIST score after CRT in patients with pCR was a partial response (PR; 10/17, three unknown), whereas in patients without a pCR, stable disease was the most common (22/26) (p = 0.002). In 26 specimens with residual tumour, this was mainly located in the periphery of the lesion rather than the centre (Spearman’s correlation = 0.67, p < 0.001). Prognosis was significantly better after a pCR compared to residual tumour (70 % 5-year overall survival vs. 20 %; p = 0.001) and in patients with fewer than 10 % vital tumour cells as compared to those with >10 % (65 % 5-year overall survival vs. 18 %; p < 0.001). A low mitotic count was associated with a longer disease-free survival (p = 0.02). Complete pathological response and the presence of fewer than 10 % vital tumour cells after pre-operative CRT are both associated with a more favourable prognosis. A modification of the pathological staging system after radiotherapy, incorporating the percentage of vital tumour cells, is proposed.
Literature
1.
go back to reference Chansky K, Sculier J-P, Crowley JJ, Giroux D, van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer staging project. Prognostic factors and pathologic TNM stage in surgically managed non small cell lung cancer. J Thor Oncol 4:729–801CrossRef Chansky K, Sculier J-P, Crowley JJ, Giroux D, van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer staging project. Prognostic factors and pathologic TNM stage in surgically managed non small cell lung cancer. J Thor Oncol 4:729–801CrossRef
2.
go back to reference Takeda S, Maeda H, Okada T, Yamaguchi T, Nakagawa M, Yokota S, Sawabata N, Ohta M (2006) Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg 30:184–189PubMedCrossRef Takeda S, Maeda H, Okada T, Yamaguchi T, Nakagawa M, Yokota S, Sawabata N, Ohta M (2006) Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg 30:184–189PubMedCrossRef
3.
go back to reference Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM (2009) Outcomes of patients with stage III non small cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115:4156–4166PubMedCrossRef Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM (2009) Outcomes of patients with stage III non small cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115:4156–4166PubMedCrossRef
4.
go back to reference Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, Klomp HM (2009) Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 36:741–746PubMedCrossRef Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, Klomp HM (2009) Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 36:741–746PubMedCrossRef
5.
go back to reference Peedell C, Dunning J, Bapusamy A (2010) Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)? Clin Oncol 22:334–346CrossRef Peedell C, Dunning J, Bapusamy A (2010) Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)? Clin Oncol 22:334–346CrossRef
6.
go back to reference Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F (2008) Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 33:829–836PubMedCrossRef Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F (2008) Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 33:829–836PubMedCrossRef
7.
go back to reference Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313–318PubMedCrossRef Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313–318PubMedCrossRef
8.
go back to reference Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469–477PubMedCrossRef Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469–477PubMedCrossRef
9.
go back to reference Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108PubMedCrossRef Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108PubMedCrossRef
10.
go back to reference Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy. The prognostic importance of the area of residual tumor. J Thor Oncol 5:49–55CrossRef Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy. The prognostic importance of the area of residual tumor. J Thor Oncol 5:49–55CrossRef
11.
12.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
13.
go back to reference Curtin F, Schulz P (1998) Multiple correlations and Bonferroni’s correction. Biol Psychiatry 44:775–777PubMedCrossRef Curtin F, Schulz P (1998) Multiple correlations and Bonferroni’s correction. Biol Psychiatry 44:775–777PubMedCrossRef
14.
go back to reference Thunnissen FB, Schuurbiers OC, den Bakker MA (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48(7):779–786PubMedCrossRef Thunnissen FB, Schuurbiers OC, den Bakker MA (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48(7):779–786PubMedCrossRef
15.
go back to reference Fischer S, Darling G, Pierre AF, Sun A, Leighl N, Waddell TK, Keshavjee S, de Perrot M (2008) Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg 33:1129–1134PubMedCrossRef Fischer S, Darling G, Pierre AF, Sun A, Leighl N, Waddell TK, Keshavjee S, de Perrot M (2008) Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg 33:1129–1134PubMedCrossRef
16.
go back to reference Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef
17.
go back to reference Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20:231–238PubMedCrossRef Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20:231–238PubMedCrossRef
18.
go back to reference Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40PubMedCrossRef Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40PubMedCrossRef
19.
go back to reference Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453–458PubMed Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453–458PubMed
20.
go back to reference Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef
21.
go back to reference Rami-Porta R, Crowley JJ, Goldstraw P (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15:4–9PubMed Rami-Porta R, Crowley JJ, Goldstraw P (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15:4–9PubMed
22.
go back to reference Goldstraw P (2009) The IASLC staging manual in thoracic oncology. Editorial Rx, Orange Park, pp 37–38 Goldstraw P (2009) The IASLC staging manual in thoracic oncology. Editorial Rx, Orange Park, pp 37–38
23.
go back to reference Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530PubMedCrossRef Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530PubMedCrossRef
Metadata
Title
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus
Authors
Johannes L. Blaauwgeers
Ingrid Kappers
Houke M. Klomp
José S. Belderbos
Lea M. Dijksman
Egbert F. Smit
Pieter E. Postmus
Marinus A. Paul
Jan W. Oosterhuis
Koen J. Hartemink
Cornelis G. Vos
Jacobus A. Burgers
Max Dahele
Erik C. Phernambucq
Birgit I. Witte
Erik Thunnissen
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 5/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1404-6

Other articles of this Issue 5/2013

Virchows Archiv 5/2013 Go to the issue